

# Joseph I Friedman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2653111/publications.pdf>

Version: 2024-02-01

31  
papers

3,566  
citations

257450

24  
h-index

501196

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

5740  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | A Multi-Phase Quality Improvement Initiative for the Treatment of Active Delirium in Older Persons. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 216-224.                        | 2.6  | 8         |
| 2  | Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 510.  | 11.0 | 63        |
| 3  | Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021, 385, 372-373.  | 27.0 | 1         |
| 4  | Modifiable factors associated with postoperative delirium after hip fracture repair. <i>European Journal of Anaesthesiology</i> , 2020, 37, 649-658.  | 1.7  | 29        |
| 5  | Copy Number Variation in Syndromic Forms of Psychiatric Illness: The Emerging Value of Clinical Genetic Testing in Psychiatry. <i>American Journal of Psychiatry</i> , 2017, 174, 1036-1050.      | 7.2  | 16        |
| 6  | Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017, 49, 27-35.  | 21.4 | 838       |
| 7  | Reply. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 498.  | 5.3  | 0         |
| 8  | Pharmacological Treatments of Non-Substance-Withdrawal Delirium: A Systematic Review of Prospective Trials. <i>American Journal of Psychiatry</i> , 2014, 171, 151-159.                           | 7.2  | 57        |
| 9  | Brain Imaging Changes Associated With Risk Factors for Cardiovascular and Cerebrovascular Disease in Asymptomatic Patients. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1039-1053.             | 5.3  | 82        |
| 10 | Novel Imaging Strategies for Assessment of Cerebrovascular Involvement. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 674-682.   | 1.9  | 0         |
| 11 | Brodmann area analysis of white matter anisotropy and age in schizophrenia. <i>Schizophrenia Research</i> , 2011, 130, 57-67.   | 2.0  | 28        |
| 12 | The effects of hypertension and body mass index on diffusion tensor imaging in schizophrenia. <i>Schizophrenia Research</i> , 2011, 130, 94-100.  | 2.0  | 8         |
| 13 | Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy. <i>Neuropsychopharmacology</i> , 2011, 36, 1289-1295.        | 5.4  | 32        |
| 14 | The Effects of Hypertension and Body Mass Index on Cognition in Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 1232-1239.  | 7.2  | 76        |
| 15 | Diffusion Tensor Imaging Findings in First-Episode and Chronic Schizophrenia Patients. <i>American Journal of Psychiatry</i> , 2008, 165, 1024-1032.  | 7.2  | 227       |
| 16 | Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia. <i>NeuroReport</i> , 2008, 19, 1369-1372.   | 1.2  | 38        |
| 17 | A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 59-63. | 1.4  | 49        |
| 18 | Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction. <i>Biological Psychiatry</i> , 2007, 62, 1396-1404.                      | 1.3  | 89        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry, 2007, 7, 25.   | 2.6  | 61        |
| 20 | Diffusion Tensor Imaging in Schizophrenia. Biological Psychiatry, 2006, 60, 1181-1187.   | 1.3  | 115       |
| 21 | Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology, 2004, 174, 45-53.  | 3.1  | 164       |
| 22 | Potential Noradrenergic Targets for Cognitive Enhancement in Schizophrenia. CNS Spectrums, 2004, 9, 350-356.   | 1.2  | 32        |
| 23 | White Matter Changes in Schizophrenia. Archives of General Psychiatry, 2003, 60, 443.  | 12.3 | 761       |
| 24 | The Course of Functional Decline in Geriatric Patients With Schizophrenia. American Journal of Geriatric Psychiatry, 2003, 11, 610-619.  | 1.2  | 2         |
| 25 | Correlates of Change in Functional Status of Institutionalized Geriatric Schizophrenic Patients: Focus on Medical Comorbidity. American Journal of Psychiatry, 2002, 159, 1388-1394.   | 7.2  | 69        |
| 26 | A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry, 2002, 51, 349-357.  | 1.3  | 170       |
| 27 | Cognition in schizophrenia. Current Psychiatry Reports, 2001, 3, 423-428.  | 4.5  | 74        |
| 28 | Guanfacine Treatment of Cognitive Impairment in Schizophrenia. Neuropsychopharmacology, 2001, 25, 402-409.   | 5.4  | 103       |
| 29 | Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biological Psychiatry, 2000, 47, 962-968.                | 1.3  | 56        |
| 30 | Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biological Psychiatry, 1999, 45, 1-16.   | 1.3  | 139       |
| 31 | The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biological Psychiatry, 1999, 46, 1243-1252. | 1.3  | 177       |